Today

Agents

Chat

Arena

Discover

More

App

Xenon submits FDA NDA for azetukalner in focal seizures - XENE News | Rallies

Xenon submits FDA NDA for azetukalner in focal seizures

XENE•2026-09-17

FDA filing for azetukalner

Xenon submitted an FDA New Drug Application for azetukalner to treat focal seizures.
The filing was supported by positive Phase 2b X-TOLE and Phase 3 X-TOLE2 data showing statistically significant cuts in monthly seizure frequency.

Related News

BlackRock Enhanced Equity Dividend Trust director Francis C. Mahoney files initial beneficial ownership statement

BDJ•2026-09-17

Abits Group announces private placement of US$16.47 million convertible note at US$14 million purchase price

ABTS•2026-09-17

Trevi Therapeutics director Michael Thomas Heffernan disposes of USD 595,329 in common shares

TRVI•2026-09-17

Granite REIT declares September distribution of CDN $0.3 per unit

GRP.U•2026-09-17

Betterware CEO Andrés Campos Chevallier acquires 45,000 shares valued at $738,04.5

BWMX•2026-09-17